Summary
Amgen Inc. (AMGN) has entered into a significant License and Collaboration Agreement with Kyowa Kirin Co., Ltd. (KKC) concerning the development and commercialization of KHK4083, a fully human monoclonal antibody targeting OX40. This agreement grants Amgen worldwide rights (excluding Japan) to lead development, manufacturing, and commercialization of the product. This collaboration represents a strategic move for Amgen to expand its pipeline in inflammation-related diseases. The financial implications of this deal include an upfront payment of $400 million from Amgen to KKC, with potential future milestone payments reaching up to $850 million. Amgen will also pay significant tiered royalties on net sales. The shared development and U.S. commercialization costs, along with Amgen booking all revenue in its territory, highlight the financial commitment and potential upside for Amgen, while KKC retains co-promotion rights in the U.S. and South Korea, and opt-in rights for other markets.
Key Highlights
- 1Amgen enters a global collaboration (ex-Japan) with Kyowa Kirin Co., Ltd. for KHK4083, an anti-OX40 monoclonal antibody.
- 2Amgen will lead development, manufacturing, and commercialization, with KKC co-promoting in the U.S. and co-marketing in South Korea.
- 3The agreement involves an immediate $400 million upfront payment from Amgen to KKC.
- 4Future contingent milestone payments could reach up to $850 million.
- 5Amgen will also pay significant tiered royalties on net sales to KKC.
- 6Development and U.S. commercialization costs will be shared between Amgen and KKC.
- 7Amgen will book all revenue from sales in its territory.